<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732626</url>
  </required_header>
  <id_info>
    <org_study_id>1.0</org_study_id>
    <nct_id>NCT02732626</nct_id>
  </id_info>
  <brief_title>The Low Voltage Guided Ablation Trail of Persistent Atrial Fibrillation</brief_title>
  <acronym>ERASE-AF</acronym>
  <official_title>The Low Voltage Guided Ablation Trail of Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mödling Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mödling Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates if the exclusion of left atrial low voltage areas / scars by ablation
      lines in addition to pulmonary vein isolation may improve the outcome in patients with
      persistent atrial fibrillation in comparison to stand alone pulmonary vein isolation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized multi center study comparing two catheter ablation
      strategies (pulmonary vein isolation (PVI) versus PVI plus low voltage areas (LVA) guided for
      ablation in patients with symptomatic persistent and long standing persistent atrial
      fibrillation (AF) who were unresponsive to at least one Class I or III antiarrhythmic agents,
      or it is the patient´s decision to receive ablation as first line therapy. Patients with
      documented persistent AF who are eligible for participation in the study, and gave a written
      informed consent, will be randomized between two groups prior to the procedure: PVI and
      PVI+LVAs guided radiofrequency catheter ablation.

      All the patients will receive a high density voltage map in sinus rhythm (SR). All the
      patients will receive circumferential PVI. If LVAs are present, Patients randomized to the
      PVI+LVA group will get additional linear ablation lines to exclude these areas from normal
      voltage atrial myocardium. The patients will be followed for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence of atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>recurrence of the first symptomatic or asymptomatic episode of atrial fibrillation within 12 months after catheter ablation procedure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>pulmonary vein isolation alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients randomized to this group receive stand alone pulmonary vein isolation regardless to their left atrial voltage map</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pulmonary vein isolation + low voltage area guided ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients randomized to this group receive pulmonary vein isolation + low voltage area guided linear substrate modification in the case if there are any</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <arm_group_label>pulmonary vein isolation alone</arm_group_label>
    <arm_group_label>pulmonary vein isolation + low voltage area guided ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic patients with persistent AF documented by 12 lead ECGs (Persistent AF is
             defined as an AF episode which lasts longer than 7 days, Persistent AF which lasted
             longer than 12 months will be defined as long standing persistent AF.)

          -  Age 18 - 80 years, both genders

          -  Patient is willing to participate in the study (signed written informed consent)

          -  Patient is willing and available to perform all follow ups.

        Exclusion Criteria:

          -  Atrial fibrillation due to reversible causes

          -  Any contraindication for AF ablation

          -  Contraindications to anticoagulation

          -  CVA/TIA in the past 6 months

          -  Previous left atrial catheter ablation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Piorkowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Schönbauer, MD</last_name>
    <phone>+432236900427020</phone>
    <email>robert.schoenbauer@moedling.lknoe.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukas Fiedler, MD</last_name>
    <phone>+432236900427017</phone>
    <email>lukas.fiedler@moedling.lknoe.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moedling Hospital</name>
      <address>
        <city>Moedling</city>
        <state>Lower Austria</state>
        <zip>2340</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Schönbauer, MD</last_name>
      <phone>+43223690040</phone>
      <email>robert.schoenbauer@moedling.lknoe.at</email>
    </contact>
    <contact_backup>
      <last_name>Lukas Fiedler, MD</last_name>
      <phone>+43223690040</phone>
      <email>lukas.fiedler@moedling.lknoe.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Elisabethinen Hospital</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Martinek, Assoc. Prof.</last_name>
      <phone>+43 732 76 76 0</phone>
      <email>Martin.Martinek@elisabethinen.or.at</email>
    </contact>
    <contact_backup>
      <last_name>Helmut Pürerfellner, Prof.</last_name>
      <phone>+43 732 76 76 0</phone>
      <email>Helmut.Puererfellner@elisabethinen.or.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Heart Center Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Huo, MD, PhD</last_name>
      <phone>+49 351 450-0</phone>
      <email>yan.huo@herzzentrum-dresden.com</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Gaspar, MD</last_name>
      <phone>+49 351 450-0</phone>
      <email>thomas.gaspar@herzzentrum-dresden.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>May 28, 2016</last_update_submitted>
  <last_update_submitted_qc>May 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

